Century Therapeutics, Inc. (IPSC) stock

IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30

$1.65+0.02 (+1.23%)

Close on Nov 13, 2026Market cap $298.77MP/E –Yield –

Century Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Century Therapeutics's total debt was $10.30M at Mar 31, 2023. For fiscal 2022 it was $10.24M, up 3.0% from the year before.

Period	Period end	Value	Change
FY2022	Dec 31, 2022	$10.24M	+3.0%
FY2021	Dec 31, 2021	$9.94M	+3.2%
FY2020	Dec 31, 2020	$9.64M	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q1 FY2023	Mar 31, 2023	$10.30M	+2.8%
Q4 FY2022	Dec 31, 2022	$10.24M	+3.0%
Q3 FY2022	Sep 30, 2022	$10.17M	+5.6%
Q2 FY2022	Jun 30, 2022	$10.10M	–
Q1 FY2022	Mar 31, 2022	$10.02M	–
Q4 FY2021	Dec 31, 2021	$9.94M	–
Q4 FY2020	Dec 31, 2020	$9.64M	–

Parsed from the XBRL in Century Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing